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Background: hERG1 channels are aberrantly expressed in human cancers. The expression, functional role and clinical significance
of hERG1 channels in pancreatic ductal adenocarcinoma (PDAC) is lacking.
Methods: hERG1 expression was tested in PDAC primary samples assembled as tissue microarray by immunohistochemistry using
an anti-hERG1 monoclonal antibody (a-hERG1-MoAb). The functional role of hERG1 was studied in PDAC cell lines and primary
cultures. ERG1 expression during PDAC progression was studied in Pdx-1-Cre,LSL-KrasG12D/þ ,LSL-Trp53R175H/þ transgenic (KPC)
mice. ERG1 expression in vivo was determined by optical imaging using Alexa-680-labelled a-hERG1-MoAb.
Results: (i) hERG1 was expressed at high levels in 59% of primary PDAC; (ii) hERG1 blockade decreased PDAC cell growth and
migration; (iii) hERG1 was physically and functionally linked to the Epidermal Growth Factor-Receptor pathway; (iv) in transgenic
mice, ERG1 was expressed in PanIN lesions, reaching high expression levels in PDAC; (v) PDAC patients whose primary tumour
showed high hERG1 expression had a worse prognosis; (vi) the a-hERG1-MoAb could detect PDAC in vivo.
Conclusions: hERG1 regulates PDAC malignancy and its expression, once validated in a larger cohort also comprising of late-
stage, non-surgically resected cases, may be exploited for diagnostic and prognostic purposes in PDAC either ex vivo or in vivo.
Pancreatic ductal adenocarcinoma (PDAC) is the most commonly
diagnosed pancreatic neoplasm, and represents the tenth most
common cause of death from cancer in both sexes combined
(Ferlay et al, 2013). Although surgery remains the cornerstone of
cure, pharmacological treatments which are currently being
applied, either as an adjuvant to surgery or as a definitive
*Correspondence: Professor A Arcangeli; E-mail: annarosa.arcangeli@unifi.it
11These authors contributed equally to the paper.
12IonTraC-Marie Curie fellow.
Received 26 August 2014; revised 2 January 2015; accepted 12 January 2015
& 2015 Cancer Research UK. All rights reserved 0007 – 0920/15
FULL PAPER
Keywords: pancreatic ductal adenocarcinoma (PDAC); hERG1 potassium channels; EGF-R; prognosis; molecular-imaging
British Journal of Cancer (2015), 1–12 | doi: 10.1038/bjc.2015.28
www.bjcancer.com | DOI:10.1038/bjc.2015.28 1Advance Online Publication: 26 February 2015
treatment for unresectable disease, have not substantially
improved the patients’ outcome (Partensky, 2013). Indeed, PDAC
5-year survival rate is still below 6% (Ferlay et al, 2013; Partensky,
2013). The main reasons of PDAC poor prognosis include
aggressive growth and a pro-invasive behaviour, which account
for rapid development of distant metastases, as well as the rapid
onset of chemoresistance. PDAC malignancy is frequently
correlated with the activation of EGF-R signalling pathways,
which in turn mediate cell proliferation and invasiveness, hence
sustaining the tumour malignancy (Boeck et al, 2013).Indeed, a
high percentage of PDAC show EGF-R overexpression, as well as
Kras mutations (Mulcahy et al, 1998; Sivecke and Crawford,
2012). Notably, and at difference from what occurs in colorectal
cancer (Krasinskas, 2011), in PDAC a mutated Kras does not
totally abrogate (or bypass) EGF-R-triggered signalling (Sivecke
and Crawford, 2012).
Traditional PDAC prognostic factors include tumour size
and grade, lymph node status, resection margins and vascular
or neural invasion. In the last few years, many studies have
been performed to identify novel biomarkers to predict the
clinical and therapeutic outcomes accurately, as well as to design
a multimodal therapeutic strategy (Apte et al, 2004). However,
none of the molecular markers described so far can be
recommended for routine clinical use (Ansari et al, 2011). The
identification of novel biomarkers that accurately predict disease
recurrence and patients’ survival would substantially improve the
identification of individual risk assessment and treatment
selection.
In the last few years, a new class of proteins has acquired
increasing relevance in oncological research: the ion channels and
transporters (ICTs). Indeed, ICTs control many ‘cancer hallmarks’
in different types of human cancers (Prevarskaya et al, 2010) and
the blockage of their activity impairs the growth of different types
of tumours, both in vitro and in vivo (Becchetti, 2011). A detailed
characterization of ICTs in different cancer types is also allowing to
exploit these proteins for diagnostic and patients’ stratification
purposes (Pedersen and Stock, 2013).
Our group contributed to this topic, focusing on channels
encoded by the human ether à-go-go-related gene 1 (hERG1).
hERG1 channels are over- and mis-expressed in a wide variety of
human cancers and their activity is involved in the regulation of
neoplastic cell growth and progression (Arcangeli, 2005). hERG1
has a clinical significance in colorectal cancer patients, where it
contributes to identify at-risk subjects (Lastraioli et al, 2012), as
well as in gastric cancer where it displays a negative prognostic
impact in T1-stage patients (Crociani et al, 2014). In both cancer
types, hERG1 is directly linked to VEGF-A and the angiogenic
pathway (Crociani et al, 2013).
Some specific ICTs have been detected and characterised in
PDAC cells: TRP cationic channels of either the ‘melastatin-
related’ (TRPM) or ‘capsaicin’ (TRPV1) type (Hartel et al, 2006),
Cl channels, in particular CLIC3 (Dozynkiewicz et al, 2012), the
sodium hydrogen exchanger 1 (HNE1) (Provost and Wallert,
2013). The latter has been recently shown to interact with the
Epidermal Growth Factor Receptor (EGF-R) in PDAC (Olszewski
et al, 2010). However none of them has been exploited for
diagnostic or prognostic purposes so far.
Only very few studies examining the role of hERG1 in human
PDAC have been produced: it was recently shown that hERG1 is
expressed in pancreatic cancer (Zhou et al, 2012), and its
expression is negatively regulated by miR-96 (Feng et al, 2014).
hERG1 silencing, as well as miR-96 over-expression inhibits the
PDAC cell growth and invasiveness in vitro, and reduces
tumorigenicity in vivo (Feng et al, 2014).
In the present paper we determined hERG1 expression and
function in PDAC and evaluated its potential as a diagnostic and
prognostic biomarker.
MATERIALS AND METHODS
Cell culture: PDAC cell lines. Cells were cultured in either RPMI-
1640 medium supplemented with 2 mM L-glutamine (MIAPaCa-2
and BxPC-3) or Dulbecco’s Modified Eagle Medium (DMEM,
Euroclone, Milan, Italy) supplemented with 4 mM L-glutamine
(PANC-1) and 10% foetal bovine serum (FBS), in a humidified 5%
CO2 atmosphere at 37 1C.
Cell culture: primary PDAC surgical samples. PDAC surgical
samples were collected during surgical procedures, and a small piece
of the tumour was put in DMEM supplemented with 4 mM
L-glutamine and kept refrigerated until use. The collected tissues
were washed three times with PBS-Gentamicin (50 mg ml 1) and
Penicillin/Streptomycin (100mg ml 1) and transferred into a petri
dish containing the ‘complete medium’ (CM) consisting of DMEM
supplemented with 4 mM L-glutamine, 15 mM Hepes buffer, 10%
heat inactivated FBS, Gentamicin (50 mg ml 1), Penicillin/Strepto-
mycin (100mg ml 1) and Amphotericin B (Fungizone, 5mg ml 1).
The tumour was finely minced with a sterile scalpel and transferred
into a sterile tube containing CM, supplemented with Liver Digest
Medium (Life Technologies, Carlsbad, CA, USA) following the
manufacturer’s instructions. The tubes were incubated under
moderate stirring at 37 1C for 45 min. After digestion, gross debris
were left to sediment, and the supernatant containing dispersed cells
was centrifuged, washed once in CM and then resuspended in a
small volume (depending on the size of the tumour sample) of CM
to have a final cell concentration of 50 000–100 000 cells per ml.
Cells were seeded onto a ‘Basement membrane’ consisting of
RPMI 5X, HEPES (50 mmol l 1), NaOH(1 mol l 1), laminin
(0.1 mg ml 1) fibronectin (1 mg ml 1), Collagen IV (1 mg ml 1)
and incubated in a humidified 5% CO2 atmosphere at 37 1C. After
24 h of incubation the medium was changed and fresh CM was
added. After further 36 h of incubation, EGF was added at
20 ng ml 1 final concentration. When needed, E4031 was added
at 40mM final concentration. After 6 h of incubation in the presence
of EGF and/or E4031, cells were photographed under an inverted
microscope, and cell vitality was assessed through the WST-1 assay
(see Supplementary Information).
RNA extraction and real-time quantitative PCR (RQ-PCR).
RNA extraction and RQ-PCR were performed as reported by
Pillozzi et al (2007). The b-actin gene was used as a standard
reference. The relative quantification of hERG1 gene expression
was performed by the DCt method. Primer sequences are reported
in Supplementary Information (Material and Methods of mole-
cular biology experiments).
Protein extraction, immunoprecipitation (IP) and Western
blotting. Whole-cell proteins were extracted from cultured cells
as reported by Crociani et al (2013). The protocol is detailed in
Supplementary Information.
Immunofluorescence (IF) laser-confocal microscopy. MIAPaCa-2,
BxPC-3 and PANC-1 were plated and on the following day were
fixed for 15 min in PBS plus 4% paraformaldehyde at room
temperature. The protocol is fully detailed in Supplementary
Information.
Study on PDAC patients and TMA construction. Once opti-
mised the IHC protocol, 44 carcinoma samples (23 males,
21 females; mean age of 62.7 years, range 27–85 years) from
consecutive, surgically resected tumours were retrieved from the
archives of the Pathology Unit, Campus Bio-Medico University in
Rome. Data on clinical variables, including sex and age were
gathered retrospectively from patients’ records. In our series of
surgically resected patients there was not a selection criteria.
Tumour-node-metastasis status classification was reassessed
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according to the Union for International Cancer Control
(Sobin et al, 2009). Follow-up data were available for 42 included
patients; none of the patients received chemotherapy or radiation
therapy as a part of a neoadjuvant program. As the patients were
all consecutive patients submitted to surgery, the majority of them
were finally classified as TNM-stage I or II patients. Patients (3 out
of the 42 patients with available follow-up data) which resulted to
belong to TNM-stage III or IV were excluded from our survival
analysis to eliminate a potential confounding factor on evaluating
the survival. The study was carried out with approval of the
Campus Bio-Medico institutional research board. Clinicopatholo-
gical data are reported in Supplementary Table S1 and TMA
construction is reported in Supplementary Information (Materials
and Methods of experiments on primary samples).
Immunohistochemistry (IHC) and scoring assessment. IHC for
hERG1 and EGF-R detection was performed as previously reported
(Lastraioli et al, 2012) using two different preparations (either
unpurified or affinity purified through a protein A column) of the
a-hERG1-MoAb directed against the S5-pore region (DIVAL
Toscana Srl). Protocols and data were compared to determine the
best experimental conditions. Proliferation index was evaluated
by performing IHC with anti-Ki67 antibody (clone MIB-1,
DAKO Cytomation, Glostrup, Denmark), as previously reported
(Lastraioli et al, 2006). IHC protocol is detailed in Supplementary
Information.
hERG1 and EGF-R expression were evaluated by an immuno-
histochemical score calculated by combining the estimate of the
percentage of immunoreactive cells (quantity score) with the estimate
of staining intensity (staining-intensity score). This method is
frequently applied in similar conditions when working with
cytoplasmic/membrane proteins (Perrone et al, 2005). The details
of the scoring system are reported in Supplementary Information
(Materials and Methods of experiments on primary samples).
In vivo experiments. All experiments involving mice were
approved by the Italian Ministry of Health. In vivo experiments
were performed at the Laboratory of Genetic Engineering for the
Production of Animal Models (LIGeMA) at the Animal House of
the University of Florence.
Six-week old, female immunodeficient nu/nu mice were used
for tumour MIA PaCa-luc2 cell implantation, as detailed in
Supplementary Information.
Pdx-1-Cre,LSL-KrasG12D/þ ,LSL- Trp53R175H/þ (KPC) trans-
genic mice (Hingorani et al, 2003, 2005) were kindly provided
from Dr DA Tuveson (Cancer Research UK, Cambridge Research
Institute, Cambridge, UK).
Fluorescent imaging was performed using the a-hERG1-MoAb.
The detailed protocol is reported in Supplementary Information.
Statistical analysis. Descriptive statistic was used to identify
associations among age, clinical-pathological characteristics and
presence of hERG1 and EGF-R using Mann–Whitney’s U-test for
continuous parameters and w2 or Fisher’s exact test for categorical
parameters. Survival analysis (disease-free survival and overall survival)
was aimed to estimate the prognostic value of these parameters. Cox-
regression model and Kaplan–Meier curves were used.
RESULTS
Analysis of hERG1 expression in PDAC. The expression of
hERG1 was first evaluated in PDAC primary samples. A plasma
membrane and cytoplasmic positivity for hERG1, with a granular
pattern was detected in malignant neoplastic cells (Figure 1A and
a, see black arrows). Stromal tissue and normal ductal epithelium
were negative for hERG1 expression (Figure 1B and b, see white
arrows). On the other hand, in agreement with functional data
(Rosati et al, 2000), beta cells in Langerhans islets expressed
hERG1 (Figure 1B and b, see black arrows).
For the purposes of the present study, 44 PDAC primary
samples assembled as TMA were analysed, and a scoring system
for hERG1 quantification was determined. Beta cells in Langerhans
islets in the corresponding healthy pancreas sample were used as a
positive internal control. hERG1 expression varied among the
whole spectrum of PDAC primary samples, from null or very low
expression to a very high expression. We applied a scoring system
(detailed in Supplementary Information), evaluating the percen-
tage of positive cells and the staining intensity in each tumour
sample in comparison with its normal counterpart (i.e. beta cells
in Langerhans islets). Figure 1C–F shows representative samples
displaying different degrees of hERG1 staining intensity. When
setting a threshold value at 6 (as detailed in Supplementary
Information), and considering (i) samples with a score value
between 0 and 5 as negative, (ii) samples between 6 and 12 as
positive, 59.1% of the samples turned out to be positive for hERG1
expression. An example of a ‘hERG1 positive’ PDAC, as well as of
the corresponding healthy pancreas, is shown in Figure 1G and H,
and relative higher magnification pictures (panels g and h,
respectively).
hERG1 expression was then evaluated in three PDAC cell lines:
PANC-1, MIAPaCa-2 and BxPC-3. We analysed hERG1 mRNA
(by RQ-PCR) and hERG1 protein (by IP and IF) levels, as well as
the functionality of the channel through the patch clamp
technique. All the PDAC cell lines expressed the hERG1 mRNA
(Figure 1I) and the hERG1 protein (Figure 1J) although at different
levels: PANC-1 cells have the highest, MIAPaCa-2 an intermediate,
whereas BxPC-3 cells the lowest level of expression. The proper
expression of the hERG1 protein at the plasma membrane level of
PDAC cells was confirmed by IF (Figure 1K), Both PANC-1 and
MIAPaCa-2 cells were positive for hERG1 immunostaining,
whereas BxPC-3 cells showed only a faint hERG1 IF signal. Setting
a threshold equal to the IF displayed by NIH-3T3 cells (taken as
negative control), 85% of PANC-1, 76% of MIAPaCa-2 and 5% of
BxPC-3 cells turned out to be positive. A high hERG1 expression,
with a dotty pattern (see arrows in Figure 1K), was evident on the
plasma membrane of PANC-1 cells and, although to a lower
extent, of MIAPaCa-2 cells. Setting a threshold equal to that shown
by the four cells indicated by the arrow in Figure 1K, 15% of
PANC-1, 9% of MIAPaCa-2 and almost none of the BxPC-3 cells
expressed the channel at high levels onto the plasma membrane.
hERG1 channels expressed in PDAC cells were functional, as
witnessed by patch clamp experiments. Figure 1L shows a
representative example of membrane currents recorded in
MIAPaCa-2 cells: traces show the typical biophysical and
pharmacological features (e.g. the blockade by the hERG1-specific
inhibitor E4031) of hERG1 currents in tumour cells (Faravelli et al,
1996; Schönherr et al, 1999). Collectively, proper hERG1 currents
were detected, in steady-state culture conditions, in 13% of
PANC-1 cells and 11% of MIAPaCa-2 cells, whereas none of the
BxPC-3 cells expressed significant hERG1 current.
On the whole, hERG1 is expressed and is functional in the
PDAC cells, although with different expression levels in the
different cell lines examined. PANC-1 and, to a lower extent,
MIAPaCa-2 cells, express the channel at significant levels.
hERG1 regulates malignancy in PDAC cells. Then, we investi-
gated whether hERG1 exerted any cancer-related function in the
PDAC cells where it is expressed. To this purpose, hERG1 channel
activity was inhibited with the hERG1-specific blocker E4031 at
40 mM final concentration as reported by Crociani et al (2013).
We found that blocking hERG1 activity inhibited PDAC cell
proliferation, measured as the number of viable cells after 72 h of
incubation (Figure 2A). The strongest inhibitory effect was evident
in PANC-1 cells (Po0.01, Student’s t-test).
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E4031 also decreased the ability of PANC-1 and in MIAPaca-2
cells to form colonies in soft agar (Po0.05 and Po0.02,
respectively (Student’s t-test)), whereas was not effective in
BxPC-3 cells, which also displayed the lowest capacity to give rise
to colonies in soft agar (Figure 2B).
Finally, we tested whether hERG1 activity affected PDAC cell
random migration on a reconstituted ‘basement’ membrane.
Figure 2C shows that PANC-1 cells, in control condition, were
motile, whereas E4031-treated cells covered a shorter distance and
migrated more slowly. These effects, well documented and
statistically significant in PANC-1 cells (Po0.05; Student’s t-test),
were less evident in MIAPaCa-2 and almost absent in BXPC-3
cells. The latter displayed a lower basal-migratory capacity.
hERG1 function was also assessed in short-term in vitro cultures
obtained from PDAC clinical samples. Figure 2D shows the results
of a representative experiment: in control culture conditions
numerous cells are present (panel a, photograph on the left), and
appear adherent to the substrate and vital (panel a, photograph on
the left). On the contrary, the same culture treated with E4031 for
6 h shows less adherent cells (panel a, photograph on the right),
which start to round up and to detach from the substrate, showing
evident signs of cytotoxicity (panel b, photograph on the right).
The E4031-induced decrease in cell vitality is further supported by
the WST-1 data (panel c).
In tumour cells hERG1 function is related to its ability to trigger
intracellular signalling pathways through the interaction with
plasma membrane proteins (Pillozzi and Arcangeli, 2010). In
search of hERG1 plasma membrane partner proteins in PDAC
cells, we found that hERG1 co-immunoprecipitated with the EGF-








































































Figure 1. hERG1 expression in PDAC primary samples. (A) IHC for hERG1 in a PDAC sample. Magnification: 50x; a: higher magnification (200x) of
the area in the black box in panel A. Arrow indicate hERG1 immunostaining at the cytoplasmic level. (B) IHC for hERG1 in a healthy pancreas.
Magnification: 50x; b: higher magnification (200x) of the area in the black box in panel B. The black arrow indicates the hERG1 immunostaining in
Langerhans islets, mainly attributable to the expression in beta cells; the white arrows indicate the lack of expression in the pancreatic stroma, as
well as in normal ductal epithelial cells. (C–F) Representative microphotographs of samples showing different hERG1 intensity are reported;
E: intensity score¼ 0; F: intensity score¼ 1; G: intensity score¼2; H: intensity score¼ 3. Magnification: 400x. (G) IHC for hERG1 in a PDAC sample
assembled in TMA. Magnification: 50x; g: higher magnification of the area in the black box in panel G. (H) IHC for hERG1 protein in the
corresponding healthy pancreatic tissue of panel G. Magnification: 50x. (I) Expression of hERG1 RNA. hERG1 transcript levels were normalised to
the b-actin gene. (J) Expression of hERG1 protein: immunoprecipitation data. Two miligrams of total cell lysates were immunoprecipitated with the
a-hERG1-MoAb and the corresponding blots were probed with a polyclonal antibody directed against the hERG1 C-terminus (C54 antibody).
The 150 kDa band (arrow) corresponds to the mature, fully glycosylated hERG1 protein; the lower band (135 kDa) represents the partially
glycosylated, immature hERG1 protein; the 50 kDa band (arrow) corresponds to the Ig used for the immunoprecipitation. (K) Expression of hERG1
protein: immunofluorescence data. In the merged images here reported, the green signal indicates the presence of hERG1 protein at the plasma
membrane and cytoplasmic levels, whereas nuclei are stained in blue by DAPI. Magnification: 60x. (L) hERG1 current in PDAC (MIAPaCa-2) cells.
Current traces (left panel) are sensitive to the specific hERG1 blocker E4031 (right panel).
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(Figure 3A). In PANC-1 cells, E4031 decreased the phosphoryla-
tion of ERK1 and ERK2, key signalling proteins downstream to
EGF-R (Neuzillet et al, 2014). This inhibitory effect of E4031 was
evident and statistically significant after 180 min of incubation in
standard culture conditions in PANC-1 cells (Po0.01; Student’s
t-test), whereas less evident in the MIAPaCa-2 cells (Figure 3B).
Consistently with the very low or null expression of hERG1, E4031
had no effect on the phosphorylation of ERK1 and ERK2 in
BxPC-3 cells and NIH-3T3 (Figure 3B).
The co-IP of hERG1 and EGF-R also occurred in PDAC
primary samples (Figure 3C). IHC experiments further confirmed
the co-expression of the two proteins in PDAC. Figure 3D shows
two consecutive sections of a representative sample: it is evident








































































































































































































































Control+EGF 40 M E4031+EGF
Figure 2. Functional role of hERG1 channels in PDAC cells. (A) Effect of E4031 on PDAC cell proliferation. PANC-1, MIAPaCa-2 and BxPC-3 cells
were seeded at 10 000 cells per well and treated at time zero with E4031 (40 mM, final concentration). The number of viable cells were estimated
through the trypan blue exclusion method at different times of incubation. (B) Effect of E4031 on PDAC cell growth in soft agar. When PDAC cell
lines were cultured in soft agar, clonal growth was inhibited significantly by hERG1-specific inhibitor E4031. Colonies were morphologically similar
and reached the same size. For PANC-1 and MIAPaCa-2 cell lines 3000 cells per plate were seeded, whereas for BxPC-3 cell line 5000 cells per
plate were seeded. (C) Effect of E4031 on migration of PDAC cells. The cell trajectories are normalised using a common starting point. Each track
represents the movement of one cell during the 5 h period. The radii of the circles represent the mean distances covered within B5 h. The method
is fully described in Supplementary Information (Materials and Methods of in vitro experiments). *Po0.05; **Po0.02; ***Po0.01 (Student’s t-test).
(D) E4031 effects on primary PDAC cells. a, b: representative microphotographs of a primary PDAC cell culture. Left panels: control cells; right
panels: E4031-treated cells. Magnification: 200x (a) and 400x (b). In panel c, a histogram showing cell viability (evaluated by WST-1 assay, as
described in Supplementary Information) in control (black bar) and E4031-treated cells (grey bar) is reported.
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mERG1 expression during PDAC progression: in vivo studies on
KPC mice. We studied the pattern of expression of the murine
homologue of hERG1, mERG1, during PDAC progression in vivo
by IHC. A widely used mouse model of PDAC, that is, KPC
transgenic mice (Hingorani et al, 2003, 2005) was used. The model
is detailed in Supplementary Information (Materials and Methods
of in vivo experiments and Supplementary Figure S2) (Figure 4A).
Once mice showed clear signs of cachexia and abdominal
distension (around 5 months of age), they were killed and
the autoptic examination revealed the presence of tumours
(Figure 4B), whose histopathological characteristics are shown in
Figure 4C and in Supplementary Information (Supplementary
Figure S3). Some of the tumours showed a high degree of tissue
organization (panels a–c) whereas others were made of islet of
tumour cells (panel d) or small groups of neoplastic cells with
extended areas of necrosis (panel e). Double-transgenic Pdx-1-
Cre,LSL- KrasG12D/þ mice were used to detect and analyse PDAC
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Figure 3. Relationships between hERG1 and EGF-R in PDAC cell lines and primary samples. (A) Co-immunoprecipitation (co-IP) of hERG1 and
EGF-R in PANC-1 and MIAPaCa-2 cells (expressing EGF-R at high levels (Supplementary Information, Supplementary Figure S1). Co-IP
experiments were performed using either a a-hERG1-MoAb (panels on the right) or the anti-EGF-R (sc-03, Santa Cruz, Dallas, TX, USA; panels on
the left) to immunoprecipitate and the same EGF-R antibody or the polyclonal antibody directed against the hERG1 C-terminus (C54 antibody) for
membrane decoration. (B) Effect of E4031 on ERK1/2 phosphorylation after 3 h treatment. NIH-3T3 cells were used as negative control. For
membrane decoration, phospho-p44/42 MAP kinase (Cell Signaling, Danvers, MA, USA) and ERK1 antibodies (C-16, Santa Cruz), that are able to
recognize both ERK1 and ERK2 total protein were used. Monoclonal anti-a-Tubulin antibody (Sigma-Aldrich) was used as a probe for a-Tubulin as
an internal loading control. ***Po0.01 (Student’s t-test). (C) Co-IP of hERG1 and EGF-R in PDAC primary samples. Co-IP experiments were
performed on a total protein extract (1 mg) pooled from three different primary PDAC samples, using the same protocol as in panel A. (D) IHC for
hERG1 and EGF-R. A representative picture of IHC staining with the two antibodies in the same tumour sample is shown. Magnification: 55x (upper
panels) and 200x (lower panels).
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Haematoxylin and Eosin staining of the four different grades of
PanIN. Notably, PanIN lesions which occurred in transgenic mice
showed the same histological features as those observed in human
patients.
mERG1 was expressed in beta cells of the Langerhans islets of
healthy pancreas, whereas no mERG1 immunoreaction was
detectable either in ductal or acinar cells (Figure 4C, left panel
‘Wild Type’). mERG1 was expressed at quite low levels and with a
focal pattern in PanIN (Figure 4C upper panels) whereas a more
diffuse and intense staining was observed in tumours of KPC mice
(Figure 4C, lower panels). A certain degree of variability could be
observed in terms of intensity and diffusion (compare the panels at
the bottom of Figure 4C).
We applied the same scoring system described above to analyse
the Pdx-1-Cre,LSL- KrasG12D/þ and KPC samples. Figure 4D
shows that in PanIN lesions which developed in Pdx-1-Cre,LSL-
KrasG12D/þ mice, mERG1 score increases (from 1 to 6) with the
severity of the lesion, being higher in PanIN3 with respect to
PanIN2 and PanIN1 lesions. In the tumours which developed in
KPC mice, the majority of the samples showed an intermediate
scoring (Figure 4E). The different score values of the single samples
shown in Figure 4C are reported in the figure legend. The
expression of the mERG1 protein in the tumours of KPC mice was
also confirmed by Western Blot analysis (Figure 4F).
Diagnostic and prognostic significance of hERG1 in PDAC: IHC
data. Given the functional role of hERG1 in PDAC, its potential
prognostic value was then established using IHC data from the
PDAC tissue samples assembled in TMA, and taking into account
the scoring groups (see MATERIALS AND METHODS).
As stated above, 26/44 (59.1%) of the samples were positive for
hERG1 expression. hERG1 positive PDAC tumours showed a
positivity to Ki67 (i.e., a high proliferative index). When applying a
20% cut-off for Ki67 expression, a statistically significant
association with hERG1 emerged (P¼ 0.035, Fisher’s exact test)
(Table 1). A representative sample, showing two consecutive
sections, clearly shows that hERG1 positive cells match with Ki67
positive cells (Supplementary Figure S4). Moreover, hERG1
expression significantly correlated with the tumour grading
(G; P¼ 0.050, Fisher’s exact test) and with EGF-R expression
(P¼ 0.027, Fisher’s exact test; Table 1).
Furthermore, survival analysis was conducted in 39 patients,
whose complete follow-up data were available. The median follow-
up was 9.3 years (IQR: 8.4–11.2). At the univariate analysis the
following variables turned out to have a significant impact on
overall survival (OS): TNM stage (II vs I: HR: 2–11 (0.98–4.56);
P¼ 0.049) and hERG1 expression (positive vs negative: HR¼ 2.23
(1.07–4.66); P¼ 0.029; Table 2). These results were confirmed at





















































































Figure 4. mERG1 expression in KPC transgenic mouse model. (A) Breeding strategy for the generation of Pdx-1-Cre,LSL-KrasG12D/þ ,LSL-
Trp53R175H/þ (KPC) triple-transgenic mice. (B) Representative photographs of macroscopic examination of organs and tumours in control (wild
type, WT), double-transgenic (Pdx-1-Cre,LSL-KrasG12D/þ ) and KPC triple-transgenic mice. Once the abdominal cavity is opened, primary PDAC
(white arrow) in KPC mice was easily detected, as compared with the normal appearing pancreas of the wild-type and double-transgenic mice
(black arrows). (C) Histological appearance of tumour masses in control (WT), double-transgenic (Pdx-1-Cre,LSL-KrasG12D/þ ) and KPC triple-
transgenic mice. Haematoxylin and Eosin (H&E; left panel of each couple of microphotographs), magnification: 400x. IHC of mERG1 in control,
double-transgenic and KPC mice (right panel of each couple of images). Representative pictures of samples showing a different score are reported
(PanIN 1A and PanIN 1B: score 1; PanIN 2: score 2; PanIN 3: score 6; KPC tumours: upper panels score 12 and 8, lower panels score 12 and 2).
Magnification: 400x. (D) Histogram summarising mERG1 score distribution in PanIN lesions developed by Pdx-1-Cre,LSL-KrasG12D/þ mice.
(E) Histogram showing mERG1 score in KPC tumour samples. (F) WBs on total lysates from normal pancreas of WT mice and tumours of KPC mice.
Protein extracts were probed using the polyclonal antibody a-C54. mERG1 specific bands showed a lower molecular weight than the expected
155 kDa and 135 kDa bands: this difference is probably owing to an alternative glycosylation pattern present in primary samples. The membrane
was further decorated with a–tubulin antibody.
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We also tested whether hERG1 expression correlated with Kras
mutation status. The cases, reported in Table 1, for which
Kras mutational status was available (24 out of 44) were all Kras
mutated (see raw data in Supplementary Table S2). Therefore, we
analysed a small subset of patients, not included in those, whose
samples were assembled in TMA, either Kras wild type (n¼ 5) or
Kras mutated (n¼ 4). No association emerged between Kras
mutation status and hERG1 expression (P¼ 0.444, Fisher’s exact
test; Supplementary Table S3).
Diagnostic and prognostic significance of hERG1 in PDAC:
in vivo optical imaging. We then determined whether hERG1
expression could be also exploited as a molecular marker for
in vivo diagnosis. For this purpose we used a-hERG1-MoAb
labelled it with Alexa-680, and tested its ability to bind hERG1
expressed in PDAC, using either (i) immunodeficient nu/nu mice,
injected into the pancreas with luciferase-transfected MIAPaCa-2
cells (MIAPaCa-2-luc-nu/nu mice) or (ii) the KPC transgenic mice
described above. The details of the two models are described in
Supplementary Information (Materials and Methods of in vivo
experiments and Supplementary Figure S5–S7).
MIAPaCa-2-luc-nu/nu mice were treated, 21 days after tumour-
cell injection (e.g., when the counts per minute reached significant
levels, but mice did not show gross signs of illness), with 100 mg of
Alexa-680-labelled a-hERG1-MoAb injected intravenously (i.v.)
and NIR images collected 3 days afterwards. As shown in
Figure 5A, a fluorescent signal was detected from the abdominal
area suggesting the distribution of the Alexa-680-labelled a-
hERG1-MoAb at tumour site level. The fluorescence signal of
the tumour masses was more clearly evident in excised organs. The
fluorescence intensities measured as cpm cm 2 in the tumour and
in normal tissues are depicted in Figure 5B.
Molecular optical imaging was also performed in KPC mice,
5-month old, after i.v. injection of Alexa-680-labelled a-hERG1-
MoAb or Alexa-680-labelled a-IGg nonspecific control antibody.
As shown in Figure 5C (right panel), a significant fluorescent signal
was detected only from the abdominal area of Alexa-680-labelled
a-hERG1-MoAb treated KPC mice, whereas only a faint signal was
present in wild-type or KPC mice treated with the control
antibody. This suggested the accumulation of the Alexa-680-
labelled a-hERG1-MoAb in the tumour site. This was confirmed
by the ex vivo imaging on different excised organs (Figure 5D and
E, right panel). Only in pancreata carrying a tumour mass a high
fluorescent signal was detected (Figure 5E, right panel, samples 9
and 10), after the subtraction of the fluorescence level of the values
obtained using the control antibody (left panels), to remove the
nonspecific fluorescence intensity. No appreciable fluorescent
signal was revealed in the other organs, such as liver, spleen or
bladder (Figure 5D).
DISCUSSION
Despite many efforts, pancreatic cancer, and its most frequent
form, the PDAC, still carries a poor prognosis. In search of
molecular markers to improve the early diagnosis and accurate
prognosis, we studied hERG1 channels in PDAC. We provide
evidence that hERG1 channels are functionally expressed in PDAC
and may be exploited, once validated, for diagnostic and prognostic
purposes in PDAC.
The expression of hERG1 in PDAC cells was analysed at
different levels with different techniques, reaching good consis-
tency in the whole set of data. Roughly half of the PDAC cell
lines expressed functional hERG1 channels at very high levels.
These results are consistent with those recently reported by Feng
et al (2014).
Interestingly, a high hERG1 expression was detected in Kras
mutated cell lines (PANC-1 and MIAPaCa-2; Deer et al, 2010).
However, no correlation between hERG1 expression and Kras
mutational status emerged in clinical samples. As activating the
mutations of Kras can concomitantly upregulate EGF-R and its
downstream signalling pathways (Bera et al, 2013), we studied such
pathway, providing evidence that hERG1 interacted with EGF-R.
Overall, hERG1 turned out to contribute to the control of EGF-R-
triggered intracellular signalling pathways, and, by this way, to the
regulation of PDAC cell proliferation and migratory activity. In
cancer cells, hERG1 is known to interact with plasma membrane-
adhesion receptors, in particular integrins (Arcangeli and
Becchetti, 2006), as well as with growth factor receptors, such as
the VEGF-R1 in leukaemia (Pillozzi et al, 2007). We demonstrate
for the first time that a physical and functional interaction of
hERG1 with EGF-R occurs in PDAC. This finding could have
relevance in PDAC where anti-EGF-R therapy, alone or in
combination with gemcitabine, did not give relevant benefits in
terms of OS in PDAC in the Canadian NCI trial (Moore et al,
2007). Hence, the understanding of EGF-R-associated molecules
could help in identifying alternative approaches. In this light, the
targeting of NHE1, which also interacts with EGF-R, with specific
inhibitors has been proven to be an exciting novel pharmacological
approach (Miraglia et al, 2005).












Female 7 (33.33) 14 (66.67) 0.373





Negative 9 (52.94) 9 (33.33) 0.027*
Positive 8 (47.06) 18 (66.67)
hERG1 and EGF-R test
Both negative 17 (41.46) 24 (58.54)
Both positive 1 (33.33) 2 (66.67)
One positive 9 (52.94) 8 (47.06)
T stage
T2 1 (14.29) 6 (85.71) 0.211
T3 17 (45.95) 20 (54.05)
N stage
N0 9 (52.94) 9 (33.33) 0.225
N1 8 (47.06) 18 (66.67)
M stage
M0 17 (41.46) 24 (58.54) 1.000
M1 1 (33.33) 2 (66.67)
Staging
I 9 (52.94) 8 (47.06) 0.561
II 8 (33.33) 16 (66.67)
IV 1 (33.33) 2 (66.67)
Grading
Grade 1 3 (100.00) 0 (0.00) 0.050*
Grade 2 11 (44.00) 14 (56.00)
Grade 3 4 (25.00) 12 (75.00)
Ki67
o20% 14 (87.50) 10 (52.63) 0.035*
X20% 2 (12.50) 9 (47.37)
Abbreviations: EGF-R¼Epidermal Growth Factor Receptor; hERG1¼ human ether a go-go
related gene 1. Significant correlations (Po0.05) are indicated in bold and marked with *.
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We also provided evidence that hERG1 is switched on during
pancreatic cancer progression as occurs in transgenic mice. In fact,
mERG1 expression turned out to be limited to the beta cells of the
Langerhans islets in wild-type mice, as in humans (Rosati et al,
2000), and no expression was detected in normal ductal cells.
However, mERG1 started to be aberrantly is expressed in ductal
cells of Pancreatic Intraepithelial Neoplasia (PanIN) lesions, fo
example, the precursors lesions of PDAC, which arise in the
pancreas of Pdx-1-Cre,LSL- KrasG12D/þmice. As PDAC carcino-
genesis progresses, as it occurs in KPC mice, mERG1 expression
increases to reach high levels in adenocarcinomas of KPC mice.
This not-obvious result is similar to what occurs in APC mice
(Fiore et al, 2013) which over-express mERG1 in the tumours they
develop in the small and large intestine, and further stresses the
relevance of hERG1 in tumour progression.
hERG1 could be proposed as a therapeutic target in oncology
(Arcangeli et al, 2009). Indeed in the present paper we provide
evidence that hERG1 blockers could inhibit PDAC cell growth and
migration in vitro. Consistently, hERG1 silencing, or miRNA-96
over-expression, has been shown to affect PDAC tumorigenicity
either in vitro or in vivo (Feng et al, 2014). However, considering
hERG1 as a therapeutic target often encounters hindrances,
because of the cardiotoxicity that many hERG1 blockers exert.
Besides designing novel therapeutic strategies or new non
cardiotoxic hERG1 blockers (Gasparoli et al, 2015), we favoured
to test the potential usefulness of hERG1 as a prognostic marker in
PDAC. To this purpose, we analysed hERG1 expression in a cohort
of 44 PDAC samples from surgically resected patients, reaching the
demonstration that: (i) roughly half of the primary PDAC samples
over-express hERG1; (ii) hERG1 expression correlates with EGF-R
expression, and with (iii) the proliferative index (measured through
the Ki67 staining); (iv) in TNM-stage I and II patients, hERG1
positive PDAC had a worse prognosis compared with the hERG1
negative. It is worth noting that in our series of surgically resected
patients there was no selection criteria. They were all consecutive
patients submitted to surgery and the majority of them were finally
classified as TNM-stage I or II patients. This is not surprising, as
surgical resection is indicated only in this category of patients,
whereas stage III patients are generally submitted, when possible,
to a preoperative neoadiuvant treatment based on chemotherapy
or radiochemotherapy. In our study we planned to compare the
hERG1 expression in PDAC cells with the normal cells in the same
specimen (e.g., the same patients). This is feasible and easy only in
resected surgical specimens; on the other hand, in the majority of
not operated patients we can have only cancer cells coming from
needle biopsy or fine needle aspiration. It can be therefore difficult
to gather normal pancreatic cells. For all these reasons, the few (3
out of 39) patients belonging to more advanced TNM stages were
excluded from our survival analysis to eliminate a potential
confounding factor on evaluating the survival. Overall, these results
suggest the possibility that hERG1 expression might have a
prognostic impact in PDAC. It will be necessary to validate these
results in a larger cohort of patients, comprising also TNM-stages
III and IV, in which hERG1 expression will be assessed in short-
term cultures, applying the method we have developed in the
present study.
All these results were obtained determining hERG1 expression
by IHC, the gold standard diagnostic tool used to assess the
presence or absence of molecular markers on tumour tissues
(Taylor, 1994). Moreover, we determined appropriate metho-
dologies and cut-off values, to facilitate the employment of a
categorical scoring system by pathologists for an easier interpreta-
tion of the results, as well as to validate the results in order to
further propose hERG1 as a potential prognostic marker. In fact,
the real prognostic impact of hERG1, and in general of ion
channels, on cancer patients’ survival is still under study and
merits great attention. For example, in acute myeloid leukaemia,
hERG1 identifies a subgroup of patients with worse prognosis
Table 2. Univariate and multivariate overall survival analyses and cumulative 1-year overall survival in stage I and II patients
Univariate analysis Final multivariate model














Female 19 15 0.684 1 (ref.) 0.869
Male 20 16 0.700 0.94 (0.46–1.92)
hERG1 test
Negative 17 12 0.882 1 (ref.) 0.029* 1 (ref.) 0.049*
Positive 22 19 0.545 2.23 (1.07–4.66) 2.12 (1.01–4.48)
EGF-R test
Negative 14 8 0.677 1 (ref.) 0.195
Positive 25 16 0.45 1.75 (0.74–4.14)
hERG1 and EGF-R test
Both negative 9 6 0.889 1 (ref.) 0.067
Both positive 17 15 0.529 2.85 (1.09–7.49)
One positive 13 10 0.769 1.47 (0.53–4.07)
TNM stage
I 16 10 0.75 1 (ref.) 0.049* 1 (ref.) 0.085
II 23 21 0.652 2.11 (0.98–4.56) 2.00 (0.91–4.41)
Grading
Grade 1 3 2 0.667 1 (ref.) 0.461
Grade 2 22 17 0.682 1.59 (0.36–6.92)
Grade 3 14 12 0.714 2.24 (0.49–10.18)
Ki67
o20% 22 16 0.727 1 (ref.) 0.346
X20% 9 8 0.667 1.53 (0.65–3.63)
Abbreviations: CI¼ confidence interval; EGF-R¼Epidermal Growth Factor Receptor; hERG1¼ human ether a go-go related gene 1; LR¼ log rank test. Significant associations (Po0.05) are
indicated in bold and marked with *.
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(Pillozzi et al, 2007), whereas in colorectal cancer, hERG1 positivity
identifies a high risk group in stage I and II patients, only when
associated to Glut-1 negativity (Lastraioli et al, 2012). We recently
showed in a huge cohort of gastric cancer patients that hERG1
expression displays a negative prognostic impact in T1-stage patients
(Crociani et al, 2014). Hence, the impact of hERG1 in cancer
progression may depend on the characteristics of the tumour sample.
Finally, the translatability of our data to the clinical setting is
further sustained by the possibility of detecting hERG1 in vivo,
using the a-hERG1-MoAb as a tracer for in vivo imaging. In fact,
the antibody, once labelled with Alexa-680, was able to detect
hERG1-expressing tumours either when PDAC cells were injected
into the pancreas of immunodeficient mice, or in transgenic KPC
mice that express mutated Kras and Trp53 in the pancreatic ductal
cells (e.g., under the control of the Pdx-1 promoter). The possibility
to exploit the a-hERG1-MoAb to target hERG1 in vivo could have
an immediate clinical fallout for the diagnosis and clinical follow-
up of PDAC. In view of the detected mERG1 expression in PanIN
lesions in transgenic mice, the possibility exists of exploiting
hERG1 for an early diagnosis of PDAC pre-cancerous lesions
(such as Intraductal papillary mucinous neoplasm and PanIN).
Finally the antibody, whose capacity to drive nanoparticles into
hERG1-expressing cells in vitro has already been proven (Sette
et al, 2013), could be used to drive nanoparticles to the tumour site
in vivo, hence opening new therapeutic perspectives (Sette et al,
2013). A similar approach has been successfully utilised by
Soroceanu et al (1999) who exploited the expression of Cl
channels in glioblastoma to utilise chlorotoxin either as a diagnostic
agent or as a vehicle for drug delivery (Sontheimer, 2008).
Overall data here provided could qualify hERG1 as a candidate
for diagnosis, prognosis and patients’ stratification in PDAC.
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Figure 5. (A) In vivo detection of Alexa-680-labelled a-hERG1-MoAb derived fluorescence. Whole-body fluorescence compared with
bioluminescence. (B) The uptake and retention of Alexa-680-labelled-hERG1-MoAb in a surgically dissected tumour (lower panel) compared with
the healthy pancreas (upper panel). Tumour tissue displayed strong signals both in vivo and ex vivo imaging. (C) Representative pictures of whole-
body in vivo imaging of Alexa-680-labelled a-IgG nonspecific control antibody (left panel) and the Alexa-680-labelled-hERG1-MoAb fluorescence.
Imaging was performed in untreated WT and KPC mice and in Ab-injected WT and KPC mice aged 5 months. Autofluorescence was subtracted
based on the signal relative to WT non-injected mouse (on the left). (D–E) In vivo imaging of the Alexa-680-labelled-hERG1-MoAb fluorescence
within dissected organs (D) and pancreas (E). Left panels: 1: organs and pancreas of untreated WT mice; 2–3: organs and pancreas of control Ab-
injected WT mice; 4–6: organs and pancreas of control Ab-injected KPC mice. Right panels: 1–2: organs and pancreas of untreated WT mice; 3–4:
organs and pancreas of untreated KPC mice; 5–7: organs and pancreas of MoAb-injected WT mice; 8–12: organs and pancreas of MoAb-injected
KPC mice; PDAC tumours are shown in the insets (9–10).
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